Literature DB >> 12823238

Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients.

P G Scheffer1, G Bos, H G F M Volwater, J M Dekker, R J Heine, T Teerlink.   

Abstract

AIMS: Oxidative modification of low-density lipoprotein (LDL) is believed to be a key step in the genesis of atherosclerotic lesions. The presence of small, dense LDL is associated with accelerated atherosclerosis and is common in diabetic patients. The aim of this study was to investigate the relationship of in vitro LDL oxidizability and circulating in vivo oxidized LDL with LDL particle size in Type 2 diabetic patients and healthy control subjects. SUBJECTS AND METHODS: The study group consisted of 58 elderly well controlled Type 2 diabetic patients and 58 control subjects with normal glucose metabolism. LDL particle size was measured by high-performance gel-filtration chromatography. In vitro oxidizability of LDL was measured by monitoring conjugated diene formation and plasma levels of circulating oxidized LDL were determined by ELISA.
RESULTS: In vitro susceptibility of LDL to oxidation was not related to plasma levels of in vivo oxidized LDL, nor to LDL particle size. In the diabetic patients, but not in the control group, an inverse relation between LDL size and in vivo oxidized LDL was observed (r=-0.35, P=0.007). This relation was strengthened after controlling for LDL-cholesterol concentration (r=-0.52, P<0.001).
CONCLUSIONS: In agreement with the view that small, dense LDL accelerates atherosclerosis, an inverse relationship was observed between LDL size and circulating in vivo oxidized LDL in Type 2 diabetic patients. Our results also suggest that in vitro susceptibility to oxidation is not a suitable surrogate measure for in vivo LDL oxidation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823238     DOI: 10.1046/j.1464-5491.2003.00975.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

1.  Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia.

Authors:  E Nobécourt; S Jacqueminet; B Hansel; S Chantepie; A Grimaldi; M J Chapman; A Kontush
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

Review 2.  Clinical significance of the physicochemical properties of LDL in type 2 diabetes.

Authors:  P G Scheffer; T Teerlink; R J Heine
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

3.  Determinants and clinical significance of plasma oxidized LDLs in older individuals. A 9 years follow-up study.

Authors:  Giovanni Zuliani; Mario Luca Morieri; Stefano Volpato; Giovanni B Vigna; Cristina Bosi; Marcello Maggio; Antonio Cherubini; Stefania Bandinelli; Jack M Guralnik; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2012-10-11       Impact factor: 5.162

4.  The effect of PPARgamma-agonism on LDL subclass profile in patients with type 2 diabetes and coronary artery disease.

Authors:  Riikka Lautamäki; Pirjo Nuutila; K E Juhani Airaksinen; Aila Leino; Heikki Hiekkanen; Marian Turiceanu; Murray Stewart; Juhani Knuuti; Tapani Rönnemaa
Journal:  Rev Diabet Stud       Date:  2006-05-10

5.  Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.

Authors:  Naila Rabbani; Lisa Godfrey; Mingzhan Xue; Fozia Shaheen; Michèle Geoffrion; Ross Milne; Paul J Thornalley
Journal:  Diabetes       Date:  2011-05-26       Impact factor: 9.461

Review 6.  Innovatively Established Analysis Method for Lipoprotein Profiles Based on High-Performance Anion-Exchange Liquid Chromatography.

Authors:  Yuji Hirowatari; Hiroshi Yoshida
Journal:  J Atheroscler Thromb       Date:  2019-09-20       Impact factor: 4.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.